All analyses
AI analysis

Singhe Hospitals PLC: research report

OvervaluedbearishNov 4, 2026

The evidence points bearish: Singhe trades at 43.9 times earnings despite profit growth, leaving a demanding valuation. The counterweight is a record September gross margin.

Reports without a focus are public, one per stock per day. Generation usually takes about 15 minutes, and we'll notify you when it's ready.

Why bearish

  • The LKR 22.10 price values trailing profit at 43.9 times, against the healthcare median of 9.9 times.
  • It values net assets at 7.5 times versus the sector median of 1.2 times, while no dividend is on record in two years.

Against this. September-quarter net profit rose 54.3% year-on-year as gross margin reached a record 71.1%.

Net margin
11.6%sector 13.0%
from 9.7% a year earlier, revenue +28.4%
Return on equity
4.7%sector 11.2%
full year to Jun 30, 2026
P/E
41.0sector 11.8
earnings Rs 0.56 per share
P/B
7.78sector 1.36
book Rs 2.96 per share
Dividend yield
0.00%sector 0.00%
trailing twelve months

Current figures, updated daily from filings to Sep 30, 2026. The report below was written on Nov 4, 2026. Sector figures are the median of 6 listed companies in the same sector.

Overview

Singhe Hospitals operates a private hospital in Ratnapura and a diagnostic laboratory and collection-centre network across Sabaragamuwa and neighbouring provinces. The latest filing shows a materially stronger September quarter, with faster revenue growth, higher profit and a gross margin that was the strongest among comparable September quarters on record.

That operational improvement sits against a demanding market valuation and no recorded dividend distribution, making the durability of the hospital and laboratory network's improved profitability central to the assessment.

Price performance

At LKR 22.10 on 4 November 2026, the share was up 99.1% over one year while the ASPI declined over the same period. It stood in the upper end of its 52-week range, only 10.8% below the high, so the current valuation follows a substantial re-rating rather than a prolonged retreat.

Recent 60-day volatility was below its own one-year norm, although trading remains very thin: median daily turnover was LKR 291,618, and a LKR 1 million order is more than everything that trades on a typical day (343% of it). The three-year record includes six falls of 15% or more, with the deepest at 28.4%; these were historical episodes, not price levels.

Valuation

At 43.9 times P/E, the market price represents 43.9 rupees for every rupee of trailing profit, versus a 9.9 times healthcare-sector median. The premium is especially notable because the latest audited-year ROE was only 4.7%, meaning the business generated under five cents of annual profit for each rupee of shareholders' equity.

The 7.5 times P/B means the market values each rupee of net assets at LKR 7.50, against a sector median of 1.2 times. Singhe's P/E is cheaper than 73% of days since April 2015, but that reflects an unusually expensive own-history record rather than a low absolute multiple. No dividend is on record in the last two years, compared with a 2.3% sector median yield. No sector-percentile anomaly was supplied.

News and sentiment

Direct company coverage is thin: there were no material Singhe Hospitals articles in the last 90 days. There are also no confirmed or pending corporate actions in the supplied record, and no dividend is on record in the past two years.

Financials

September-quarter revenue rose 28.4% year-on-year to LKR 608.2 million and net profit increased 54.3% to LKR 70.6 million. The profit improvement is meaningful because it came with higher sales rather than a lower revenue base, though the latest filing does not provide an operating-profit line to separate operating performance from finance costs and tax.

Gross margin rose from 68.1% to 71.1%, while net margin improved from 9.7% to 11.6%; the gross margin was the best of eight comparable September quarters and the net margin was also the best of eight. Operating margin was not available in the latest filing, versus 14.3% a year earlier. The margin evidence therefore supports a stronger underlying September result, but does not fully show the path from gross profit to net profit.

Equity reached LKR 1.3 billion at September, up from LKR 1.0 billion a year earlier, strengthening the capital base behind the hospital and laboratory operations. The current ordinary share count is 431.3 million; no latest-balance-sheet share count was supplied, so no per-share trend is inferred.

Risks

The foremost risk is that earnings improvement has already been capitalised into a valuation well above healthcare peers: a 43.9 times P/E leaves the profit supporting the share price exposed if the recent margin strength proves difficult to sustain.

Balance-sheet risk is presently moderate rather than acute. At the June 2026 audited year-end, debt was 12.7% of owners' equity and operating profit covered interest 10.58 times, so borrowings were modest relative to equity and interest costs were covered more than ten times. The current ratio was 1.84 times, meaning it had LKR 1.84 of short-term assets, including receivables and supplies, for each LKR 1 of bills due within a year.

Cash conversion was 0.83 times in that audited year, so not all accounting operating profit arrived as operating cash. Free cash flow was still positive at LKR 35.7 million, but capital expenditure consumed a meaningful part of operating cash generation. As at 4 November 2026, higher inflation, fuel costs and bond yields form a less benign operating backdrop, although the supplied data does not quantify their effect on Singhe.

Outlook

As at 4 November 2026, the next material company event is the interim filing for the quarter ending 31 December 2026, expected between 2 and 14 February 2027. It will show whether the September improvement in revenue, gross margin and profit extended beyond one quarter, or whether the premium valuation rests on an isolated result.

The data does not provide patient volumes, test volumes, pricing, capacity additions or contract developments, so it cannot identify which hospital or laboratory activity drove the stronger September outcome. Healthcare-sector regulatory and public-procurement developments are relevant environmental context, but no supplied evidence ties them to Singhe's earnings.

About this report. Generated on Nov 4, 2026 from market data up to Nov 4, 2026, 0 material news articles over 90 days and financials to Sep 30, 2026, and scored 6 of 100 on value (overvalued) when it was written. Every figure is drawn from EquityLK's own data on this company. AI research can contain errors, so treat it as a starting point, not investment advice.

Previous reports